ADNI data is made available to researchers around the world. As such, there are many active research projects accessing and applying the shared ADNI data. To further encourage Alzheimer’s disease research collaboration, and to help prevent duplicate efforts, the list below shows the specific research focus of the active ADNI investigations. This information is requested annually as a requirement for data access.
| Principal Investigator | |
| Principal Investigator's Name: | Birgitte Brock |
| Institution: | Aarhus University |
| Department: | Department of Biomedicine |
| Country: | |
| Proposed Analysis: | Primarily to investigate whether 6 months of treatment with the long-acting GLP-1 receptor agonist liraglutide will affect the intra-cerebral Aβ deposit in the CNS of patients with AD assessed by PIB PET scan. Secondly, to examine changes in glucose uptake in the CNS by FDG PET scan before and after treatment with liraglutide. Further, to validate the cognitive functions using a specific neuro-psychological test battery before and after treatment with liraglutide. Finally, to evaluate changes in MR-scans and global oxidative RNA and DNA stress before and after treatment with liraglutide. |
| Additional Investigators | |
| Investigator's Name: | Lærke Egefjord |
| Proposed Analysis: | Primarily to investigate whether 6 months of treatment with the long-acting GLP-1 receptor agonist liraglutide will affect the intra-cerebral Aβ deposit in the CNS of patients with AD assessed by PIB PET scan. Secondly, to examine changes in glucose uptake in the CNS by FDG PET scan before and after treatment with liraglutide. Further, to validate the cognitive functions using a specific neuro-psychological test battery before and after treatment with liraglutide. Finally, to evaluate changes in MR-scans and global oxidative RNA and DNA stress before and after treatment with liraglutide. |
| Investigator's Name: | Michael Gejl |
| Proposed Analysis: | Primarily to investigate whether 6 months of treatment with the long-acting GLP-1 receptor agonist liraglutide will affect the intra-cerebral Aβ deposit in the CNS of patients with AD assessed by PIB PET scan. Secondly, to examine changes in glucose uptake in the CNS by FDG PET scan before and after treatment with liraglutide. Further, to validate the cognitive functions using a specific neuro-psychological test battery before and after treatment with liraglutide. Finally, to evaluate changes in MR-scans and global oxidative RNA and DNA stress before and after treatment with liraglutide. |
| Investigator's Name: | Arne Møller |
| Proposed Analysis: | Primarily to investigate whether 6 months of treatment with the long-acting GLP-1 receptor agonist liraglutide will affect the intra-cerebral Aβ deposit in the CNS of patients with AD assessed by PIB PET scan. • Secondly, to examine changes in glucose uptake in the CNS by FDG PET scan before and after treatment with liraglutide. • Further, to validate the cognitive functions using a specific neuro-psychological test battery before and after treatment with liraglutide. • Finally, to evaluate changes in MR-scans and global oxidative RNA and DNA stress before and after treatment with liraglutide. |
| Investigator's Name: | Hans Brændgaard |
| Proposed Analysis: | Primarily to investigate whether 6 months of treatment with the long-acting GLP-1 receptor agonist liraglutide will affect the intra-cerebral Aβ deposit in the CNS of patients with AD assessed by PIB PET scan. • Secondly, to examine changes in glucose uptake in the CNS by FDG PET scan before and after treatment with liraglutide. • Further, to validate the cognitive functions using a specific neuro-psychological test battery before and after treatment with liraglutide. • Finally, to evaluate changes in MR-scans and global oxidative RNA and DNA stress before and after treatment with liraglutide. |
| Investigator's Name: | Hanne Gottrup |
| Proposed Analysis: | Primarily to investigate whether 6 months of treatment with the long-acting GLP-1 receptor agonist liraglutide will affect the intra-cerebral Aβ deposit in the CNS of patients with AD assessed by PIB PET scan. • Secondly, to examine changes in glucose uptake in the CNS by FDG PET scan before and after treatment with liraglutide. • Further, to validate the cognitive functions using a specific neuro-psychological test battery before and after treatment with liraglutide. • Finally, to evaluate changes in MR-scans and global oxidative RNA and DNA stress before and after treatment with liraglutide. |
| Investigator's Name: | Jørgen Rungby |
| Proposed Analysis: | Primarily to investigate whether 6 months of treatment with the long-acting GLP-1 receptor agonist liraglutide will affect the intra-cerebral Aβ deposit in the CNS of patients with AD assessed by PIB PET scan. • Secondly, to examine changes in glucose uptake in the CNS by FDG PET scan before and after treatment with liraglutide. • Further, to validate the cognitive functions using a specific neuro-psychological test battery before and after treatment with liraglutide. • Finally, to evaluate changes in MR-scans and global oxidative RNA and DNA stress before and after treatment with liraglutide. |
| Investigator's Name: | Albert Gjedde |
| Proposed Analysis: | Primarily to investigate whether 6 months of treatment with the long-acting GLP-1 receptor agonist liraglutide will affect the intra-cerebral Aβ deposit in the CNS of patients with AD assessed by PIB PET scan. • Secondly, to examine changes in glucose uptake in the CNS by FDG PET scan before and after treatment with liraglutide. • Further, to validate the cognitive functions using a specific neuro-psychological test battery before and after treatment with liraglutide. • Finally, to evaluate changes in MR-scans and global oxidative RNA and DNA stress before and after treatment with liraglutide. |